mobile-logo

March 2015

03 Mar

First contract for a clinical version of our Virtual Tumour model (“Virtual Tumour Clinical”) with Global Pharmaceutical Company, Merck (Merck Serono)

by 16by9
in Investor News / RNS
Comments

Physiomics plc is pleased to announce that it has signed its first contract for developing Virtual Tumour Clinical with a global pharmaceutical company. The client is Merck Serono, the biopharmaceutical division of Merck, Germany. Revenue from the contract will fall in the 2014/2015 and 2015/2016 financial years and is in the region of the total value of all of Physiomics 2013/2014 sales. As such it...

Read More
07 Jan

36th EORTC-PAMM Winter Meeting

by 16by9
in Other News
Comments

Dr Christophe Chassagnole will be speaking on Translational modelling of vemurafenib, selumetinib and docetaxel in metastatic melanoma with virtual tumour on Thursday 22nd January at 11:10am. For more information please visit www.pamm2015.com...

Read More